Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative | Molecular Psychiatry
Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline | SpringerLink
Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification | Alzheimer's Research & Therapy | Full Text
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia | Nature Medicine
Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals | medRxiv
![Phosphorylated Tau T181 ELISA Kit Wako・298-81701[Detail Information] | [Life Science]|Laboratory Chemicals-FUJIFILM Wako Chemicals U.S.A. Corporation](https://labchem-wako.fujifilm.com/us/product_data/images/03666535_img02.png "Phosphorylated Tau T181 ELISA Kit Wako・298-81701[Detail Information] | [Life Science]|Laboratory Chemicals-FUJIFILM Wako Chemicals U.S.A. Corporation")
Phosphorylated Tau T181 ELISA Kit Wako・298-81701[Detail Information] | [Life Science]|Laboratory Chemicals-FUJIFILM Wako Chemicals U.S.A. Corporation
Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease | EMBO Molecular Medicine
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression | Alzheimer's Research & Therapy | Full Text
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study - The Lancet Neurology
Plasma pTau181 as a biomarker for Alzheimer's disease - Meng - 2020 - MedComm - Wiley Online Library
Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis - Karikari - 2021 - Alzheimer's & Dementia - Wiley Online Library
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia | Nature Medicine
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts - The Lancet Neurology
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected | EMBO Molecular Medicine
Phospho-Tau (Thr181) antibody (28866-1-AP) | Proteintech
Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease | Alzheimer's Research & Therapy | Full Text
Associations of plasma p-tau181 baseline levels and longitudinal... | Download Scientific Diagram
Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline | SpringerLink
Frontiers | Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study
